argenx SE
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
18 mrt 2015 - 17:49
Statutaire naam
argenx SE
Titel
arGEN-X Reports Fourth Quarter Business Update And Full Year 2014 Financial Results
Bericht
Management to host conference call today at 6 pm CET / 1 pm EDT
18 March 2015
Breda, the Netherlands / Ghent, Belgium - arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced its fourth quarter business update and the consolidated full year results for 2014, which have been prepared in accordance with IFRS as adopted by the European Union.
Datum laatste update: 21 februari 2026